AS902330 30 microgram (mcg) [clinicaltrials_resource:a5589bdd35346c1756fd9f666ab639d3]
intervention [clinicaltrials_vocabulary:intervention]
AS902330 30 microgram (mcg) [clinicaltrials_resource:a5589bdd35346c1756fd9f666ab639d3]
Bio2RDF identifier
a5589bdd35346c1756fd9f666ab639d3
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:a5589bdd35346c1756fd9f666ab639d3
arm group [clinicaltrials_vocabulary:arm-group]
intervention desc [clinicaltrials_vocabulary:intervention-desc]
AS902330 will be administered ...... ks, with follow-up to 2 years.
intervention name [clinicaltrials_vocabulary:intervention-name]
AS902330 30 microgram (mcg)
other name [clinicaltrials_vocabulary:other-name]
Sprifermin
identifier
clinicaltrials_resource:a5589bdd35346c1756fd9f666ab639d3
title
AS902330 30 microgram (mcg)
@en
type
label
AS902330 30 microgram (mcg) [clinicaltrials_resource:a5589bdd35346c1756fd9f666ab639d3]
@en